Medical Pharmacology Question Bank
Chapter: Chapter 11 — Lipid Disorders — Module: Module 5 — Non-Statin Lipid-Lowering Therapy Part 2: Fibrates, Niacin, Bile Acid Sequestrants, and Omega-3 Fatty Acids
Tier: T1 — Tier 1 Core Concept Questions (16 Questions)
1. A third-year resident asks why fenofibrate, unlike most prodrugs that require hepatic CYP activation, does not carry significant CYP-mediated drug interaction risk with statins. Which of the following correctly describes the activation pathway of fenofibrate and its pharmacokinetic implication?
ANSWER: B
Rationale:
Fenofibrate is a prodrug converted to fenofibric acid — its pharmacologically active form — by esterases present in intestinal mucosa, plasma, and liver tissue. This ester hydrolysis does not involve cytochrome P450 enzymes and, critically, does not inhibit CYP2C9 or the glucuronidation pathways by which most statins are conjugated for elimination. As a result, fenofibrate does not significantly impair statin clearance and carries a substantially lower myopathy and rhabdomyolysis risk when combined with statins compared to gemfibrozil. Gemfibrozil, by contrast, inhibits CYP2C9 and glucuronidation of statin lactone forms, raising plasma statin concentrations and markedly increasing the risk of statin-induced myopathy — a distinction with major clinical prescribing implications. Option A) is incorrect because fenofibrate activation does not involve CYP3A4; esterase hydrolysis is the correct mechanism, and CYP competition is not the basis for fibrate-statin interaction differences. Option C) is incorrect because fenofibric acid is produced by esterase hydrolysis, not CYP2C8 oxidation; gemfibrozil's interaction with statins involves glucuronidation inhibition, not fenofibrate activation interference. Option D) is incorrect because gut lumen lipase activation is not the correct mechanism; esterase hydrolysis occurs post-absorption in intestinal mucosa, plasma, and liver — not in the gut lumen prior to absorption. Option E) is incorrect because fenofibrate requires metabolic activation to fenofibric acid and is not a direct-acting compound; selective adipose distribution does not explain its interaction profile.
2. A 58-year-old man with mixed dyslipidemia is on rosuvastatin 20 mg daily. His physician considers adding a fibrate for persistent hypertriglyceridemia (triglycerides 620 mg/dL). Which of the following best explains why gemfibrozil is specifically contraindicated with most statins, whereas fenofibrate is the preferred fibrate for statin combination therapy?
ANSWER: D
Rationale:
Gemfibrozil is contraindicated with most statins because it is a potent inhibitor of CYP2C9 and, more importantly, of the glucuronidation pathway responsible for conjugating statin lactone forms to their acyl glucuronide metabolites for elimination. This impairs statin clearance, raises plasma statin concentrations significantly, and substantially increases the risk of myopathy and rhabdomyolysis. The interaction is pharmacokinetic in mechanism and applies broadly across the statin class. Fenofibrate, activated by ester hydrolysis rather than CYP-dependent metabolism, does not inhibit CYP2C9 or glucuronidation pathways and therefore does not meaningfully raise statin plasma levels — making it the appropriate fibrate when combination therapy is clinically necessary. Option A) is incorrect because the myopathy risk from gemfibrozil is pharmacokinetic (impaired statin elimination), not an indirect consequence of differential triglyceride lowering or VLDL receptor saturation. Option B) is incorrect because gemfibrozil's primary interaction with statins involves glucuronidation inhibition, not CYP3A4 inhibition; CYP3A4 is the relevant pathway for simvastatin and lovastatin but the gemfibrozil interaction operates through a different mechanism. Option C) is incorrect because gemfibrozil does undergo hepatic metabolism; direct mitochondrial toxicity independent of pharmacokinetic statin interaction is not the established mechanism of myopathy risk. Option E) is incorrect because protein displacement is not the established mechanism of the gemfibrozil-statin interaction; the interaction is mediated through impaired conjugative metabolism, not competition for albumin binding.
3. A 62-year-old man with type 2 diabetes mellitus (T2DM) and mixed dyslipidemia is on simvastatin 40 mg daily with well-controlled LDL-C but persistent hypertriglyceridemia (triglycerides 310 mg/dL) and low HDL-C (38 mg/dL). His cardiologist considers adding fenofibrate. Which of the following most accurately describes what the ACCORD Lipid trial demonstrated regarding this combination strategy?
ANSWER: A
Rationale:
The ACCORD Lipid trial randomized patients with T2DM on simvastatin to receive fenofibrate or placebo, targeting the clinically common phenotype of mixed dyslipidemia with elevated triglycerides and low HDL-C. Despite producing the expected lipid changes — triglyceride reduction and HDL-C increase — fenofibrate added to simvastatin did not significantly reduce the primary composite cardiovascular endpoint (non-fatal MI, non-fatal stroke, or CV death) compared to simvastatin alone. A pre-specified subgroup analysis suggested possible benefit in patients with the highest triglycerides and lowest HDL-C, but this finding was not statistically robust enough to change guidelines. ACCORD Lipid fundamentally reshaped the clinical role of fibrates by demonstrating that lipid metric improvement does not necessarily translate to cardiovascular event reduction when added to background statin therapy. Option B) is incorrect because ACCORD Lipid found no significant reduction in non-fatal MI and did not generate a Class I ACC/AHA guideline recommendation for routine fibrate-statin combination in T2DM. Option C) is incorrect because ACCORD Lipid was not terminated early for rhabdomyolysis; the trial completed its planned follow-up and the safety profile of fenofibrate-simvastatin was acceptable. Option D) is incorrect because fenofibrate did not worsen glycemic control or increase hypoglycemia or cardiovascular death in ACCORD Lipid; the glycemic arm was a separate ACCORD sub-study. Option E) is incorrect because the subgroup signal in ACCORD Lipid was in patients with high TG and low HDL-C — not specifically women; a sex-specific prescribing recommendation was not adopted in ADA guidelines based on this trial.
4. A pharmacology lecturer asks students to identify the primary molecular target through which niacin (nicotinic acid) reduces free fatty acid (FFA) flux from adipose tissue and secondarily lowers VLDL (very low-density lipoprotein) synthesis in the liver. Which of the following correctly identifies this mechanism?
ANSWER: C
Rationale:
Niacin's primary lipid-lowering mechanism operates through GPR109A, a Gi-coupled receptor expressed at high density on adipocytes. Agonist binding activates the Gi protein, which inhibits adenylyl cyclase and reduces intracellular cAMP. The resulting reduction in cAMP suppresses protein kinase A (PKA), which in turn reduces phosphorylation and activation of hormone-sensitive lipase (HSL) — the enzyme responsible for triglyceride hydrolysis within adipocytes. The net effect is decreased FFA (free fatty acid) release from adipose tissue into the portal and systemic circulation. Since FFA flux to the liver is the primary substrate driving hepatic VLDL-triglyceride synthesis and secretion, reduced adipose lipolysis translates directly to reduced VLDL production and lower plasma triglycerides. GPR109A activation also mediates niacin's cutaneous flushing via prostaglandin D2 release from skin Langerhans cells — a separate receptor-mediated effect on a different tissue. Option A) is incorrect because AMPK-mediated ACC suppression is the mechanism of metformin's and fibrate's partial hepatic effects; niacin's primary mechanism is adipocyte GPR109A agonism, not direct hepatic AMPK activation. Option B) is incorrect because niacin does not inhibit HMG-CoA reductase; its mechanism is entirely distinct from statins and operates through adipocyte FFA suppression rather than cholesterol synthesis inhibition. Option D) is incorrect because niacin reduces FFA mobilization by suppressing HSL activity (reducing lipolysis), not by inhibiting DGAT2 or enhancing adipose oxidative capacity. Option E) is incorrect because LPL upregulation via PPARγ is the mechanism of thiazolidinediones; niacin acts through a Gi-coupled receptor mechanism on adipocytes, not through a nuclear receptor transcriptional program.
5. A 49-year-old woman with dyslipidemia starts niacin extended-release 1 g nightly. She calls the clinic 30 minutes after her first dose reporting intense facial flushing, warmth, and tingling. Her nurse asks the prescribing resident what caused this reaction and how it can be prevented. Which of the following best explains the mechanism of niacin-induced flushing and the pharmacologic basis for its prevention?
ANSWER: E
Rationale:
Niacin-induced flushing is a GPR109A-mediated prostaglandin effect, distinct from the receptor's lipid-lowering actions. GPR109A is expressed on skin Langerhans cells and keratinocytes as well as adipocytes. In the skin, GPR109A activation triggers phospholipase A2-mediated arachidonic acid release and subsequent COX-mediated synthesis of prostaglandin D2 (PGD2). PGD2 binds DP1 receptors on cutaneous blood vessels, producing vasodilation and the characteristic flushing, warmth, and tingling that occurs 15–60 minutes after dosing. Pre-treatment with aspirin 325 mg (or another NSAID) 30 minutes before niacin administration inhibits COX activity, reduces PGD2 synthesis, and substantially attenuates flushing in most patients. Taking niacin with food and slow dose titration also reduce flushing severity. Tolerance to flushing typically develops with continued use as COX-mediated PGD2 responses down-regulate. Option A) is incorrect because flushing is prostaglandin D2-mediated, not histamine-mediated; H2 antihistamines are not an established preventive strategy for niacin flushing. Option B) is incorrect because niacin flushing is a pharmacodynamic prostaglandin effect at GPR109A, not an IgE-mediated hypersensitivity reaction; it occurs on first exposure and does not require prior sensitization. Option C) is incorrect because the flushing mechanism involves GPR109A and PGD2 in skin cells, not adrenergic receptor activation from a hepatic nicotinamide metabolite; beta-blockers are not used for this purpose. Option D) is incorrect because TRPV1 channel activation is not the established mechanism of niacin flushing; while food co-administration does blunt absorption peaks and modestly reduce flushing, the principal pharmacologic prevention strategy is aspirin-mediated COX inhibition.
6. A cardiology fellow reviews the evidence base for niacin therapy. She asks why niacin is no longer recommended as routine adjunctive therapy in patients already on statin treatment, despite its favorable effects on HDL-C (high-density lipoprotein cholesterol) and triglycerides. Which of the following best describes what the HPS2-THRIVE trial demonstrated?
ANSWER: B
Rationale:
The HPS2-THRIVE (Heart Protection Study 2 — Treatment of HDL to Reduce the Incidence of Vascular Events) trial randomized over 25,000 high-risk patients on effective statin-based LDL-C lowering to extended-release niacin 2 g combined with laropiprant (a DP1 receptor antagonist designed to reduce flushing) or placebo. Despite the expected improvements in HDL-C and triglycerides, niacin plus laropiprant produced no significant reduction in the primary composite cardiovascular endpoint compared to placebo. Moreover, the combination was associated with a significant excess of serious adverse events including new-onset diabetes, myopathy, serious gastrointestinal symptoms, and bleeding events. These findings — negative efficacy and increased harm — effectively ended the clinical use of niacin as routine adjunctive therapy in patients already achieving adequate LDL-C lowering on statins. The trial was interpreted as evidence that raising HDL-C pharmacologically does not translate to cardiovascular event reduction when LDL-C is already adequately controlled. Option A) is incorrect because HPS2-THRIVE did not show a significant cardiovascular benefit; it was the absence of benefit combined with increased adverse events — not hepatotoxicity causing trial termination — that defined the result. Option C) is incorrect because the trial's negative result was not attributed to laropiprant's vascular effects; the interpretation is that niacin-mediated HDL-C raising provides no incremental benefit on background statin therapy, regardless of flushing suppression. Option D) is incorrect because HPS2-THRIVE found no significant reduction in non-fatal MI or any cardiovascular endpoint; no Class IIb guideline recommendation for niacin in post-MI patients resulted from this trial. Option E) is incorrect because HPS2-THRIVE enrolled patients on background statin therapy — not statin-intolerant patients — and did not test niacin monotherapy as a statin alternative.
7. A medical student asks the attending physician to explain how bile acid sequestrants (BAS) such as cholestyramine and colesevelam lower LDL-C (low-density lipoprotein cholesterol) without being absorbed into the systemic circulation. Which of the following best describes the mechanism?
ANSWER: D
Rationale:
Bile acid sequestrants — cholestyramine, colestipol, and colesevelam — are large, non-absorbable cationic exchange resins or polymers that bind negatively charged bile acids in the intestinal lumen via ionic interactions. By trapping bile acids and preventing their reabsorption in the terminal ileum, BAS interrupt the enterohepatic circulation through which approximately 95% of secreted bile acids are normally reclaimed. The resulting hepatic bile acid deficit activates CYP7A1 — the rate-limiting enzyme for de novo bile acid synthesis from cholesterol — driving increased conversion of hepatic cholesterol to bile acids. As hepatic free cholesterol is consumed in this process, sterol-regulatory element-binding protein 2 (SREBP-2) is activated, upregulating LDL receptor expression on hepatocyte membranes. The increased LDL receptor density enhances LDL-C uptake from plasma, lowering circulating LDL-C by 15–30%. Because BAS are never absorbed, they carry no systemic pharmacokinetic interactions and have an excellent safety profile for systemic toxicity. Option A) is incorrect because BAS are not absorbed and do not reach the liver; they act entirely within the intestinal lumen and do not directly inhibit CYP7A1 through a systemic mechanism. Option B) is incorrect because BAS do not bind NPC1L1 sites or directly block cholesterol absorption; ezetimibe acts via NPC1L1 inhibition, not BAS; BAS lower LDL-C through bile acid trapping and the downstream effect on hepatic cholesterol metabolism. Option C) is incorrect because BAS lower FXR activation by removing bile acids from the ileal lumen — this is partially accurate mechanistically — but the description of FXR suppression releasing CYP7A1 inhibition is a secondary element; the primary driver emphasized clinically is the hepatic cholesterol-to-bile-acid conversion following reduced recirculation, not FXR pathway detail. Option E) is incorrect because BAS do not reduce absorptive mucosal surface area, and PCSK9 downregulation is not the established mechanism linking BAS use to LDL receptor upregulation; the mechanism involves SREBP-2 activation from reduced hepatic cholesterol.
8. A 54-year-old woman with type 2 diabetes mellitus (T2DM), LDL-C 148 mg/dL, and a history of myalgia limiting statin use is being evaluated for lipid-lowering options. Her endocrinologist notes that one bile acid sequestrant has an additional FDA (Food and Drug Administration)-approved indication relevant to her diabetes management. Which agent and indication is being referenced?
ANSWER: C
Rationale:
Colesevelam is the only bile acid sequestrant with an FDA-approved indication for improving glycemic control as adjunctive therapy in adults with type 2 diabetes, in addition to its LDL-C lowering indication. In clinical trials, colesevelam reduced HbA1c by approximately 0.5% when added to background antidiabetic therapy. The precise mechanism of glycemic benefit is not fully characterized, but proposed mechanisms include: altered bile acid signaling through FXR and TGR5 receptors in intestinal L-cells that enhances GLP-1 (glucagon-like peptide-1) secretion; modification of the gut microbiome bile acid pool; and potential effects on hepatic glucose production. This dual indication makes colesevelam a rational choice in patients like this one — statin-intolerant with concurrent T2DM requiring both LDL-C lowering and glycemic management, though its glycemic effect is modest and it is not a substitute for established antidiabetic therapy. Option A) is incorrect because cholestyramine has no FDA-approved glycemic indication; it does not bind disaccharides or act analogously to alpha-glucosidase inhibitors. Option B) is incorrect because colestipol has no FDA-approved indication for glycemic control; while bile acid sequestration can influence incretin biology, colestipol has not been approved for this use. Option D) is incorrect because cholestyramine has no approved indication for HbA1c reduction or AGE excretion; this mechanism is not established for any BAS. Option E) is incorrect because colesevelam's approved glycemic indication is for management of established T2DM as adjunctive therapy, not prevention of progression from pre-diabetes; direct beta-cell GPR119 activation by portal bile acid metabolites is not the established mechanism.
9. A 67-year-old man with LDL-C of 158 mg/dL and fasting triglycerides of 620 mg/dL is referred for lipid management. His primary care physician asks whether a bile acid sequestrant would be appropriate for his LDL-C elevation. Which of the following best describes the key contraindication and its mechanism in this patient?
ANSWER: C
Rationale:
Bile acid sequestrants are contraindicated when fasting triglycerides exceed approximately 500 mg/dL — and used with caution even at triglycerides above 300 mg/dL — because their mechanism of action stimulates hepatic synthesis of new bile acids from cholesterol via CYP7A1. This increased demand for cholesterol substrate activates SREBP-1c, which also upregulates hepatic fatty acid and triglyceride synthesis, driving increased VLDL-triglyceride secretion. In patients with already elevated triglycerides and impaired VLDL clearance, this compensatory VLDL upregulation can cause substantial further triglyceride rises, increasing the risk of acute pancreatitis — a dangerous complication of severe hypertriglyceridemia (typically triglycerides >1,000 mg/dL). For this patient with triglycerides of 620 mg/dL, a BAS is contraindicated; fibrate therapy or high-dose omega-3 fatty acids would be the preferred initial interventions to reduce hypertriglyceridemia and pancreatitis risk. Option A) is incorrect because impaired pancreatic lipase activity and fat malabsorption via micellar disruption is not the mechanism of BAS contraindication in hypertriglyceridemia; the concern is worsening of plasma triglycerides through VLDL upregulation, not fat digestion impairment. Option B) is incorrect because BAS do not activate FXR — they reduce bile acid-mediated FXR activation by sequestering bile acids; apoC-III upregulation via FXR is not the mechanism of BAS-related triglyceride worsening. Option D) is incorrect because BAS do not block intestinal chylomicron assembly receptors; the contraindication threshold is approximately 500 mg/dL, not all hypertriglyceridemia, and chylomicron receptor blockade is not the mechanism. Option E) is incorrect because BAS do not cause hepatic steatosis, and impaired VLDL clearance at LDL receptors is not the mechanism of BAS-related triglyceride worsening; the effect is on VLDL secretion, not clearance.
10. A 63-year-old man with established atherosclerotic cardiovascular disease (ASCVD) and fasting triglycerides of 285 mg/dL is on maximally tolerated rosuvastatin with LDL-C at goal. His cardiologist considers adding icosapentaenoic acid ethyl (IPE) 4 g/day based on recent outcomes data. Which of the following most accurately describes what the REDUCE-IT trial demonstrated regarding this therapy?
ANSWER: B
Rationale:
The REDUCE-IT (Reduction of Cardiovascular Events with Icosapentaenoic Acid-Intervention Trial) randomized approximately 8,000 statin-treated patients with fasting triglycerides 135–499 mg/dL and either established cardiovascular disease or diabetes with additional cardiovascular risk factors to IPE 4 g/day or mineral oil placebo. The trial demonstrated a 25% relative risk reduction in the primary composite endpoint of cardiovascular death, non-fatal MI, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina. Total cardiovascular events were reduced by approximately 30%. This was a landmark outcome given the historical failure of other triglyceride-lowering strategies — fibrates and DHA-containing omega-3 formulations — to demonstrate cardiovascular benefit on background statin therapy. FDA approved IPE (Vascepa) for cardiovascular risk reduction in this patient population based on REDUCE-IT results. The mechanism driving the cardiovascular benefit beyond triglyceride reduction remains debated, with proposed contributions from membrane stabilization, anti-inflammatory and anti-platelet effects of EPA incorporation. Option A) is incorrect because REDUCE-IT did demonstrate significant cardiovascular event reduction — approximately 25% relative risk reduction — which is precisely why IPE earned FDA approval for this indication. Option C) is incorrect because IPE's cardiovascular benefit in REDUCE-IT was not attributed to LDL-C lowering from VLDL conversion; the mechanism is more complex and EPA-specific effects are proposed beyond simple triglyceride-to-LDL conversion. Option D) is incorrect because while IPE is associated with a modest increased risk of atrial fibrillation (a known class effect of omega-3 agents), REDUCE-IT was not terminated for arrhythmia, and the FDA did approve IPE for cardiovascular risk reduction based on the trial's positive results. Option E) is incorrect because REDUCE-IT enrolled patients with triglycerides 135–499 mg/dL and the benefit was not restricted to the severe hypertriglyceridemia subgroup; the approved indication covers the broader enrolled population, not solely patients above 500 mg/dL.
11. A cardiology fellow asks why the STRENGTH trial — which tested a high-dose omega-3 formulation containing both EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — failed to demonstrate cardiovascular benefit, while REDUCE-IT using IPE (icosapentaenoic acid ethyl, a pure EPA formulation) showed a 25% relative risk reduction. Which of the following best characterizes the STRENGTH finding and the prevailing mechanistic hypothesis for the divergent results?
ANSWER: A
Rationale:
The STRENGTH trial (Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in High CV Risk PatienTs with Hypertriglyceridemia) randomized statin-treated patients with elevated triglycerides to omega-3 carboxylic acids (4 g/day, containing both EPA and DHA) or corn oil placebo. Unlike REDUCE-IT, STRENGTH found no significant reduction in major adverse cardiovascular events and was terminated early for futility. This divergence from REDUCE-IT's positive result with pure IPE has generated considerable debate. The leading mechanistic hypothesis is that DHA, when co-administered with EPA, competes with EPA for incorporation into cell membrane phospholipids, potentially displacing EPA from membranes and attenuating the membrane-stabilizing, anti-platelet, and anti-inflammatory effects attributed to high-tissue EPA concentrations — effects that may drive IPE's cardiovascular benefit. A secondary controversy involves REDUCE-IT's mineral oil placebo, which some investigators argue raised LDL-C and inflammatory biomarkers in the comparator group, inflating apparent IPE benefit; STRENGTH's corn oil placebo is considered more biologically neutral. Both trials lowered triglycerides comparably, suggesting triglyceride reduction alone does not explain IPE's benefit. Option B) is incorrect because STRENGTH used 4 g/day — the same total dose as REDUCE-IT — not a subtherapeutic 1 g/day dose; dose difference does not explain the divergent results. Option C) is incorrect because STRENGTH was terminated for futility (no efficacy signal), not for hemorrhagic stroke events; no FDA restriction on high-dose omega-3 formulations to triglycerides above 500 mg/dL resulted from STRENGTH. Option D) is incorrect because STRENGTH did not show subgroup cardiovascular benefit at high triglycerides; the trial was uniformly neutral across triglyceride levels, and no triglyceride threshold subgroup showed significant benefit. Option E) is incorrect because while DHA-containing formulations do modestly raise LDL-C more than pure EPA formulations, a 18–22% LDL-C rise is an exaggeration; current guidelines do not universally recommend pure EPA over combination products for all cardiovascular indications based on LDL-C differences alone.
12. A 58-year-old woman on colesevelam for LDL-C lowering also takes levothyroxine, warfarin, and lisinopril. Her pharmacist flags a potential drug interaction concern. Which of the following best describes the interaction risk with bile acid sequestrants and the recommended management strategy?
ANSWER: C
Rationale:
Bile acid sequestrants can adsorb a wide variety of drugs within the intestinal lumen through ionic exchange and physical binding mechanisms. Drugs with known significant absorption impairment include levothyroxine, warfarin, digoxin, fat-soluble vitamins (A, D, E, K), thiazide diuretics, and certain statins. Because BAS remain entirely within the intestinal lumen, the interaction is purely physicochemical — the BAS binds the co-administered drug in the gut contents before it can be absorbed. The established management strategy is temporal separation: affected drugs should be taken at least 1–4 hours before (most commonly recommended) or 4–6 hours after the BAS dose. Colesevelam, the newest BAS, has a somewhat more selective binding profile and may have fewer interactions than cholestyramine or colestipol, but temporal separation remains prudent for all drugs with narrow therapeutic windows. For this patient, levothyroxine and warfarin should both be timed carefully relative to colesevelam administration, and INR should be monitored after BAS initiation. Option A) is incorrect because while warfarin absorption is impaired by BAS co-administration, warfarin is not absolutely contraindicated with BAS; temporal separation of doses is sufficient management in most patients. Option B) is incorrect because BAS reduce (not increase) absorption of co-administered drugs; they do not displace drugs from albumin binding sites — BAS are non-absorbable and never reach systemic circulation where albumin binding occurs. Option D) is incorrect because BAS are not absorbed and therefore cannot inhibit CYP2C9; warfarin interaction is due to reduced warfarin absorption in the gut lumen, not impaired hepatic metabolism. Option E) is incorrect because while fat-soluble vitamin absorption is impaired by BAS and vitamin K depletion can theoretically affect INR, empiric warfarin dose reduction by a fixed percentage is not the recommended approach; INR monitoring and temporal drug separation are preferred over empiric dose adjustments.
13. A 71-year-old man with stage 3b chronic kidney disease (CKD, eGFR 32 mL/min/1.73m²) starts fenofibrate 145 mg daily for triglycerides of 480 mg/dL. Two weeks later his serum creatinine has risen from 1.6 to 2.1 mg/dL. His nephrologist is concerned about nephrotoxicity. Which of the following best explains this finding?
ANSWER: B
Rationale:
Fenofibrate is well-documented to cause a reversible increase in serum creatinine that does not represent true nephrotoxicity or structural renal injury. The mechanism is inhibition of creatinine tubular secretion, likely through competition at proximal tubule organic cation and anion transporters, which reduces the renal clearance of creatinine — a tubularly secreted solute — without affecting glomerular filtration. Studies measuring iothalamate or inulin clearance have confirmed that true GFR is not reduced by fenofibrate-associated creatinine rises. The creatinine elevation typically stabilizes and reverses upon discontinuation. Despite being a non-nephrotoxic effect, clinical guidelines recommend dose reduction when eGFR is 30–60 mL/min/1.73m² and avoidance when eGFR falls below 30 mL/min/1.73m², partly because the creatinine rise makes CKD monitoring unreliable and because fenofibric acid accumulation may occur with severe renal impairment. For this patient with eGFR 32, fenofibrate should be dose-reduced or discontinued; gemfibrozil is an alternative, though gemfibrozil-statin combination risk must be considered separately. Option A) is incorrect because fenofibrate does not cause true nephrotoxicity via ROS-mediated tubular necrosis; the creatinine rise is a reversible pharmacokinetic phenomenon affecting tubular secretion, not structural injury. Option C) is incorrect because COX-2 inhibition causing hemodynamic GFR reduction is the mechanism by which NSAIDs affect renal function — not fenofibrate; fenofibrate has no significant COX-2 inhibitory activity. Option D) is incorrect because while fenofibrate does activate PPARα in skeletal muscle, increased creatine turnover and CPK upregulation as the mechanism for creatinine rise has not been established; the accepted mechanism is reduced tubular secretion of creatinine, not increased creatinine generation. Option E) is incorrect because while fenofibric acid does accumulate in CKD and dose adjustment is required, functional prerenal azotemia from OAT3 saturation is not the established mechanism; the documented effect is on creatinine secretion specifically, not global tubular cation/anion transport causing azotemia.
14. A 52-year-old man with dyslipidemia, gout, and borderline elevated fasting glucose (102 mg/dL) is started on immediate-release niacin with a plan to titrate to 2 g/day for HDL-C raising. Three months later his uric acid has risen from 7.2 to 9.8 mg/dL, his fasting glucose is 128 mg/dL, and his ALT (alanine aminotransferase) is three times the upper limit of normal. Which of the following best describes the set of adverse metabolic effects attributable to niacin and their mechanisms?
ANSWER: D
Rationale:
Niacin has three well-established metabolic adverse effects: hyperglycemia, hyperuricemia, and hepatotoxicity. Niacin worsens insulin resistance and glucose tolerance — the precise mechanism is incompletely understood but likely involves a rebound in FFA flux following the acute suppression of adipose lipolysis via GPR109A, with the FFA surge impairing peripheral insulin-stimulated glucose uptake. This worsening of glucose metabolism is a clinically significant concern in patients with pre-diabetes or T2DM and contributed to the risk-benefit reassessment of niacin therapy. Niacin reduces renal uric acid excretion by competing with urate at organic anion transporter (OAT) sites in the proximal tubule responsible for uric acid secretion, raising serum urate levels — particularly relevant in patients with gout or borderline hyperuricemia. Hepatotoxicity is strongly associated with sustained-release (SR) or extended-release niacin formulations at doses above approximately 2 g/day; immediate-release niacin at comparable doses is less hepatotoxic, though ALT elevation can occur with any formulation. The development of all three adverse effects in this patient warrants dose reduction or discontinuation. Option A) is incorrect because beta-cell toxicity via nicotinamide riboside accumulation is not the mechanism of niacin-induced hyperglycemia; xanthine oxidase competitive inhibition is not the mechanism of hyperuricemia; and NAD+ depletion-driven mitochondrial dysfunction is not the established mechanism of niacin hepatotoxicity. Option B) is incorrect because the reduction in FFA-amplification of insulin secretion is not the primary mechanism of niacin-induced hyperglycemia; the dominant effect is on peripheral insulin resistance; and calling hepatotoxicity idiosyncratic mischaracterizes a known dose- and formulation-dependent effect. Option C) is partially correct mechanistically regarding insulin resistance and hepatotoxicity but incorrectly states that niacin raises uric acid by competing at tubular secretion transporters — niacin reduces uric acid excretion (raising urate) by competing at secretion sites, which is actually what option D. Option E) is incorrect because NAD+ excess driving xanthine oxidase, glycogen phosphorylase, and mitochondrial uncoupling is not the established mechanistic framework for niacin's three main adverse metabolic effects.
15. A pharmaceutical representative discusses a new selective PPARα modulator (SPPARMα) called pemafibrate with a lipidologist, noting that it was designed to produce greater triglyceride lowering with fewer off-target effects than traditional fibrates. The lipidologist asks about the cardiovascular outcomes evidence for pemafibrate. Which of the following best describes what the PROMINENT trial demonstrated?
ANSWER: E
Rationale:
The PROMINENT (Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes) trial randomized patients with T2DM, mild-to-moderate hypertriglyceridemia, and low HDL-C on background statin therapy to pemafibrate or placebo. Pemafibrate is a selective PPARα modulator engineered to produce stronger PPARα activation with fewer off-target effects than traditional fibrates. Despite achieving robust triglyceride reduction (approximately 26%) and improvements in other lipid parameters including apoC-III reduction, pemafibrate did not reduce — and in fact numerically slightly increased — the primary composite cardiovascular endpoint of non-fatal MI, non-fatal stroke, coronary revascularization, or cardiovascular death compared to placebo. PROMINENT joins ACCORD Lipid and FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) in demonstrating that fibrate-class lipid metric improvements do not translate to cardiovascular event reduction when added to statin-based LDL-C lowering. The trial effectively closed the door on the hypothesis that triglyceride-targeted fibrate therapy provides additive cardiovascular benefit on background statin therapy in patients with T2DM. Option A) is incorrect because PROMINENT found no significant cardiovascular event reduction; pemafibrate did not produce an 18% relative risk reduction and is not established as a preferred fibrate for cardiovascular risk reduction in diabetic dyslipidemia. Option B) is incorrect because PROMINENT was not terminated for myopathy; it completed follow-up and was terminated for futility given the absence of cardiovascular benefit. Option C) is incorrect because PROMINENT did not demonstrate a statistically significant reduction in cardiovascular events driven by unstable angina hospitalizations or any other endpoint; the trial result was uniformly neutral to negative. Option D) is largely accurate mechanistically (pemafibrate did reduce TG and apoC-III without cardiovascular benefit) but understates the finding — the primary composite actually numerically favored placebo slightly, making option E the more complete and accurate characterization.
16. A researcher studying the differential cardiovascular outcomes between pure EPA (icosapentaenoic acid) and DHA (docosahexaenoic acid)-containing omega-3 formulations proposes a membrane biology hypothesis. Which of the following best describes the mechanistic basis by which high-dose pure EPA supplementation — but not EPA+DHA combination products — may confer cardiovascular benefit through cell membrane effects?
ANSWER: C
Rationale:
The prevailing membrane biology hypothesis for the divergent cardiovascular outcomes between pure EPA (IPE, Vascepa) and EPA+DHA combination formulations centers on competitive membrane phospholipid incorporation. Cell membrane phospholipids are dynamic structures in which omega-3 and omega-6 fatty acids compete for esterification at the sn-2 position. Studies have shown that DHA has a higher affinity for membrane phospholipid incorporation than EPA. When EPA and DHA are co-administered, DHA preferentially displaces EPA from the sn-2 position of membrane phospholipids — potentially preventing the membrane-stabilizing, anti-arrhythmic, and anti-inflammatory effects that have been attributed to high-tissue EPA concentrations. When only EPA is supplemented at high dose (4 g/day), plasma and cell membrane EPA concentrations rise substantially without the competitive displacement from DHA, allowing membrane EPA enrichment to reach levels that may drive the cardioprotective effects observed in REDUCE-IT. Supporting evidence includes analyses showing that REDUCE-IT patients achieving higher on-treatment plasma EPA levels had greater cardiovascular event reductions. This hypothesis remains debated — additional proposed mechanisms include EPA's anti-oxidant effects on LDL particles, plaque stabilization, and the role of mineral oil placebo in REDUCE-IT potentially worsening the comparator arm. Option A) is incorrect because DHA does not directly activate thromboxane synthase in platelets; differential thromboxane A2 reduction is not the established primary mechanism distinguishing pure EPA from combination EPA+DHA cardiovascular outcomes. Option B) is incorrect because while EPA and DHA both contribute to resolvin biosynthesis, competitive inhibition of E-series resolvin production by DHA via 15-lipoxygenase competition is not the established mechanistic explanation for differential cardiovascular trial outcomes. Option D) is incorrect because pure EPA is not a selective IP receptor agonist, and DHA does not act as a competitive IP receptor antagonist; the prostacyclin receptor competition hypothesis is not the established mechanistic framework for REDUCE-IT vs STRENGTH divergence. Option E) is incorrect because DHA is not preferentially converted to series-2 prostanoids by COX-1; DHA competes with arachidonic acid and serves as substrate for series-3 prostanoids similarly to EPA; the described shift in prostanoid series production is an oversimplification that does not reflect established eicosanoid biochemistry.